Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Other Neuroendocrine Carcinoma”

98 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 98 results

Early research (Phase 1)Study completedNCT01048892
What this trial is testing

Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features

Who this might be right for
Adrenocortical CarcinomaGastrointestinal Carcinoid TumorKidney Cancer+3 more
Children's Oncology Group 22
Testing effectiveness (Phase 2)UnknownNCT05675605
What this trial is testing

TY-1091 in Patients With Advanced Solid Tumors

Who this might be right for
RET-altered Non Small Cell Lung CancerMedullary Thyroid CancerRET-altered Papillary Thyroid Cancer+1 more
TYK Medicines, Inc 248
Testing effectiveness (Phase 2)Study completedNCT02404441
What this trial is testing

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Who this might be right for
MelanomaNon-small Sell Lung Cancer (NSCLC)Triple Negative Breast Cancer+2 more
Novartis Pharmaceuticals 319
Not applicableApproved For MarketingNCT03906331
What this trial is testing

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Who this might be right for
Non Small Cell Lung CancerMedullary Thyroid CancerColon Cancer+4 more
Eli Lilly and Company
Testing effectiveness (Phase 2)Looking for participantsNCT07016230
What this trial is testing

Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)

Who this might be right for
Metastatic/Locally Advanced Small-Cell Lung CancerMetastatic/Locally Advanced Poorly Differentiated NECMetastatic/Locally Advanced High-grade MTC
Gustave Roussy, Cancer Campus, Grand Paris
Not applicableActive Not RecruitingNCT03728842
What this trial is testing

Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma

Who this might be right for
Melanoma; Renal Cell Carcinoma
Indiana University 19
Early research (Phase 1)Looking for participantsNCT04119024
What this trial is testing

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Who this might be right for
Metastatic Malignant Solid NeoplasmMetastatic MelanomaPathologic Stage IIIC Cutaneous Melanoma AJCC v8+14 more
Anusha Kalbasi 18
Early research (Phase 1)Not Yet RecruitingNCT07177937
What this trial is testing

DXC014 in Patients With Advanced Solid Tumors.

Who this might be right for
Small Cell Lung CancerMelanomaProstate Cancer+1 more
Hangzhou DAC Biotechnology Co., Ltd. 150
Testing effectiveness (Phase 2)Study completedNCT02936323
What this trial is testing

PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers

Who this might be right for
Neuroendocrine TumorsCarcinoma, Small Cell LungNeuroendocrine Carcinoma
Tarveda Therapeutics 89
Testing effectiveness (Phase 2)Study completedNCT00378482
What this trial is testing

A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

Who this might be right for
Colorectal NeoplasmsMelanomaProstatic Neoplasms+3 more
AstraZeneca 37
Testing effectiveness (Phase 2)Study completedNCT04993677
What this trial is testing

SEA-CD40 Given With Other Drugs in Cancers

Who this might be right for
MelanomaCarcinoma, Non-Small- Cell Lung
Seagen Inc. 77
Testing effectiveness (Phase 2)WithdrawnNCT04276597
What this trial is testing

Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.

Who this might be right for
Pulmonary Neuroendocrine NeoplasmPheochromocytomaParaganglioma+7 more
Excel Diagnostics and Nuclear Oncology Center
Testing effectiveness (Phase 2)Looking for participantsNCT07278479
What this trial is testing

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

Who this might be right for
Large Cell Neuroendocrine CarcinomaLarge Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC)Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)+4 more
Molecular Partners AG 138
Early research (Phase 1)Study completedNCT02857270
What this trial is testing

LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

Who this might be right for
Advanced CancerMetastatic MelanomaMetastatic Non-small Cell Lung Cancer+1 more
Eli Lilly and Company 210
Early research (Phase 1)UnknownNCT00391300
What this trial is testing

Bioelectric Field Imaging in Diagnosing Melanoma and Other Skin Cancers in Patients With Skin Lesions

Who this might be right for
Melanoma (Skin)Non-melanomatous Skin Cancer
Eastern Virginia Medical School 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT04010357
What this trial is testing

Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC

Who this might be right for
Small-cell Lung CancerLarge Cell Neuroendocrine Carcinoma of the LungExtrapulmonary Small Cell Carcinoma
Case Comprehensive Cancer Center 14
Testing effectiveness (Phase 2)Active Not RecruitingNCT06287463
What this trial is testing

Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

Who this might be right for
Advanced Solid TumorRAF MutationRAS Mutation+7 more
Deciphera Pharmaceuticals, LLC 140
Testing effectiveness (Phase 2)Ended earlyNCT02452424
What this trial is testing

A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors

Who this might be right for
MelanomaNon-small Cell Lung CancerSquamous Cell Carcinoma of the Head and Neck+2 more
Daiichi Sankyo 78
Large-scale testing (Phase 3)Ended earlyNCT04588246
What this trial is testing

Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Lung Non-Small Cell CarcinomaMetastatic Lung Small Cell Carcinoma+9 more
NRG Oncology 19
Not applicableLooking for participantsNCT07138716
What this trial is testing

Research on the Application of 68Ga-DOTA-CCK-FS PET/CT in MTC

Who this might be right for
Medullary Thyroid Carcinoma
Luo Yaping 30
Load More Results
40